La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Clinuvel Pharmaceuticals Croissance future
Future contrôle des critères 6/6
Clinuvel Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 26.8% et de 22.5% par an respectivement. Le BPA devrait croître de de 26.3% par an. Le rendement des capitaux propres devrait être 20.8% dans 3 ans.
Informations clés
26.8%
Taux de croissance des bénéfices
26.3%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 14.4% |
Taux de croissance des recettes | 22.5% |
Rendement futur des capitaux propres | 20.8% |
Couverture par les analystes | Good |
Dernière mise à jour | 25 Jul 2024 |
Mises à jour récentes de la croissance future
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
6/30/2027 | 183 | 82 | 91 | 93 | 2 |
6/30/2026 | 113 | 43 | 55 | 52 | 6 |
6/30/2025 | 97 | 36 | 31 | 45 | 6 |
6/30/2024 | 87 | 34 | 29 | 42 | 6 |
12/31/2023 | 82 | 30 | 36 | 42 | N/A |
9/30/2023 | 80 | 30 | 36 | 40 | N/A |
6/30/2023 | 78 | 31 | 36 | 37 | N/A |
3/31/2023 | 74 | 29 | 39 | 40 | N/A |
12/31/2022 | 70 | 26 | 43 | 44 | N/A |
9/30/2022 | 68 | 24 | 41 | 42 | N/A |
6/30/2022 | 66 | 21 | 39 | 40 | N/A |
3/31/2022 | 62 | 22 | 33 | 34 | N/A |
12/31/2021 | 57 | 24 | 27 | 27 | N/A |
9/30/2021 | 53 | 24 | 23 | 23 | N/A |
6/30/2021 | 48 | 25 | 18 | 19 | N/A |
3/31/2021 | 43 | 23 | N/A | N/A | N/A |
12/31/2020 | 38 | 21 | 17 | 19 | N/A |
9/30/2020 | 35 | 18 | 15 | 16 | N/A |
6/30/2020 | 33 | 15 | 13 | 14 | N/A |
3/31/2020 | 32 | 15 | N/A | N/A | N/A |
12/31/2019 | 32 | 15 | 16 | 16 | N/A |
9/30/2019 | 32 | 16 | 17 | 17 | N/A |
6/30/2019 | 31 | 18 | 18 | 18 | N/A |
3/31/2019 | 29 | 17 | 16 | 17 | N/A |
12/31/2018 | 27 | 16 | 15 | 15 | N/A |
9/30/2018 | 26 | 15 | 13 | 13 | N/A |
6/30/2018 | 25 | 13 | 12 | 12 | N/A |
3/31/2018 | 21 | 10 | 10 | 10 | N/A |
12/31/2017 | 17 | 6 | 8 | 8 | N/A |
9/30/2017 | 17 | 7 | N/A | 9 | N/A |
6/30/2017 | 17 | 7 | N/A | 10 | N/A |
3/31/2017 | 14 | 5 | N/A | 7 | N/A |
12/31/2016 | 12 | 3 | N/A | 4 | N/A |
9/30/2016 | 9 | 0 | N/A | -1 | N/A |
6/30/2016 | 7 | -3 | N/A | -5 | N/A |
3/31/2016 | 5 | -5 | N/A | -5 | N/A |
12/31/2015 | 4 | -6 | N/A | -5 | N/A |
9/30/2015 | 4 | -8 | N/A | -5 | N/A |
6/30/2015 | 3 | -10 | N/A | -5 | N/A |
3/31/2015 | 3 | -10 | N/A | -5 | N/A |
12/31/2014 | 3 | -10 | N/A | -5 | N/A |
9/30/2014 | 3 | -8 | N/A | -5 | N/A |
6/30/2014 | 3 | -6 | N/A | -5 | N/A |
3/31/2014 | 3 | -6 | N/A | -6 | N/A |
12/31/2013 | 2 | -6 | N/A | -7 | N/A |
9/30/2013 | 2 | -6 | N/A | -7 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CUV ( 26.8% par an) est supérieure au taux d'épargne ( 2.4% ).
Bénéfices vs marché: Les bénéfices de CUV ( 26.8% par an) devraient croître plus rapidement que le marché Australian ( 13.1% par an).
Croissance élevée des bénéfices: Les bénéfices de CUV devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de CUV ( 22.5% par an) devrait croître plus rapidement que le marché Australian ( 5.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de CUV ( 22.5% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de CUV devrait être élevé dans 3 ans ( 20.8 %)